Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors
The combination of bortezomib with clofarabine demonstrated limited antitumor effects possibly due to the inability to reach the efficacious doses achieved in preclinical models.
Authors
- Jennifer Zlott
- Brandon Miller (ORCID: https://orcid.org/0000-0003-1523-9092)
- Deborah Wilsker
- William G. Herrick (ORCID: https://orcid.org/0000-0003-1570-3641)
- Murielle Hogu
- Richard Piekarz (ORCID: https://orcid.org/0000-0002-3591-7893)
- Ralph E. Parchment
- Jibran Ahmed (ORCID: https://orcid.org/0000-0002-3412-7689)
- Kate Ferry-Galow
- Laura Kuhlmann
- Shivaani Kummar
- Apurva K. Srivastava (ORCID: https://orcid.org/0000-0002-6390-7553)
- Karen Gray
- Naoko Takebe (ORCID: https://orcid.org/0000-0002-5790-4954)
- Jeevan Prasaad Govindharajulu (ORCID: https://orcid.org/0000-0002-3705-4120)
- Robert Meehan
- Mohamad A. Salkeni (ORCID: https://orcid.org/0000-0002-7222-1967)
- James H. Doroshow
- Li Li
- Lamin Juwara
- Geraldine O’Sullivan-Coyne
- Andre DeSouza
- Sarah Shin
- Alice P. Chen
- Lawrence Rubinstein
Institutions
- Leidos (United States) (US)
- National Institutes of Health (US)
- Oregon Health & Science University (US)
- National Cancer Institute (UA)
- Oklahoma State University Oklahoma City (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- University of Oklahoma (US)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1007/s00280-026-04868-y
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health